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A B S T R A C T   
The Granada group in BNCT research is currently performing studies on: nuclear and radiobiological data for 
BNCT, new boron compounds and a new design for a neutron source for BNCT and other applications, including 
the production of medical radioisotopes. All these activities are described in this report.   
1. Introduction 
Boron Neutron Capture Therapy (BNCT), which has recently shown 
very promising results (Barth et al., 2012), is now facing a renaissance 
with the introduction of a new generation of accelerator based BNCT 
centers expected soon (Kreiner et al., 2016). 
The Granada group started a few years ago a strong activity in BNCT 
research, being the first one in Spain. This group is formed by re-
searchers of the Departments of Atomic, Molecular and Nuclear Physics, 
Biochemistry and Molecular Biology and Immunology of the University 
of Granada, and of the University Hospital “Virgen de las Nieves” in 
Granada, and sustains collaborations with international research in-
stitutions as the Institute Laue-Langevin (ILL) of Grenoble (France), the 
European Center for Nuclear Research (CERN) of Geneva (Switzerland), 
and with national institutes as the National Accelerator Center of Seville 
or the Institute for Material Sciences of Barcelona. 
The aim of this research activity is to pursue improvements for this 
very promising form of radiotherapy in whose potential we believe. The 
research lines include:  
� the reduction of uncertainties for improving the accuracy of the 
treatment planning,  
� the design of the optimal neutron beam for BNCT from a particle 
accelerator, 
� the search of new boron compounds which may improve the selec-
tivity, and  
� exploring new avenues as the use of another cooperative isotope as a 
neutron capturer or the application of neutron guides for a potential 
BNCT-based radiosurgery with cold or thermal neutrons. 
As a side project, and from a relevant exchange of ideas with the 
physicians at the Department of Nuclear Medicine, we studied the pos-
sibility of producing medical radioisotopes from an accelerator suitable 
for BNCT, with the aim of increasing the potential applications of a new 
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facility. This has produced stimulating results that shows the possibility 
of producing new radiopharmaceuticals for advanced diagnostic 
methods. 
The main goal of this project has led to the conceptual design of a 
multi-purpose facility which will allow performing BNCT clinical trials 
as well as other scientific applications. Our aim is to incorporate in the 
future clinical trials the results from our research, which will be dis-
cussed in this review, as well of the most recent advances from the very 
active BNCT community. 
2. Reducing uncertainties in BNCT treatment planning 
The analysis of the current data from BNCT clinical trials shows a 
clear improvement of the treatment outcome with the delivered dose. In 
order to optimize the treatments, it is a key task to reduce the un-
certainties associated with the determination of the dose at the organs of 
risk. We have studied some of these sources of uncertainty. 
2.1. Nuclear data for Monte Carlo simulations for BNCT. measurements 
at n_TOF (CERN) 
BNCT treatment planning has made use of Monte Carlo simulations 
for the neutron transport and for the calculation of the physical dose 
delivered both at tumor and at normal tissues. In the reference dose 
calculations of Goorley et al. (2002), the spectral neutron flux that is 
obtained by codes like MCNPX (Pelowitz, 2005) at any point in the 
phantom is integrated with cross-section dependent kerma factors in 
order to obtain the physical dose. 
Currently, in BNCT the physical dose is calculated as the sum of three 
contributions: the neutron dose Dn, the boron dose, DB, and the gamma 
dose, Dγ. The neutron dose is usually separated as: the fast dose Df , from 
the secondary particles (mainly hydrogen recoils) produced by neutrons 
with energy above 0.5 eV and the thermal dose Dt, for neutrons with 
energy below 0.5 eV (Goorley et al., 2002; IAEA, 2001). The latter is 
dominated by the 14N (n,p) reaction and sometimes it is also called the 
nitrogen dose (Joensuu et al., 2003). The gamma dose is delivered by 
any photons from the own beam contamination as well as the 2.224 MeV 
photons from the hydrogen capture of thermal neutrons inside the 
phantom. 
The International Commission on Radiation Units and Measurements 
(ICRU) recommends for conventional radiotherapy that the un-
certainties of every step of the treatment should be kept well below 5% 
(ICRU, 1978). For BNCT, we have examined the role of the knowledge of 
the cross sections as possible sources of uncertainty in the determination 
of the prescribed dose. In clinical trials, the dose delivered to a10B 
loaded tumor is due to 10B (n,α)7Li, whose cross section is very well 
known (it is a standard reference), being much higher than the sum of all 
the other reactions. However, for the delivered dose to the normal tissue, 
which is a limiting factor in the treatment planning for the organs at risk, 
the other components are very important. As said above, the 14N (n, 
p)14C reaction dominates the thermal dose. There is a fair amount of 
experimental data on this reaction, with cross section spanning over 
several different energy ranges. However, the existing discrepancies are 
important and relevant for BNCT dosimetry and also for astrophysics 
(element nucleosynthesis) (Praena et al., 2017). From 61 meV to 35 keV, 
there is only one differential measurement, Koehler and O’Brien 
(Koehler et al., 1989), therefore the evaluations are based on it, but its 
extrapolation to thermal energy does not match the most recent results 
of Wagemans et al. (2001). There are discrepancies at the thermal point 
of about 50% in the experimental values reported in EXFOR database 
(Zerkin and Pritychenko, 2018). This uncertainty has important conse-
quences in BNCT because of the crucial importance of the 14N (n,p)14C 
reaction on the delivered dose to normal tissue. 
For this reason a proposal for the measurement of this cross section 
for thermal and epithermal energies at the neutron time of flight (n_TOF) 
facility at CERN was presented and approved by the INTC committee in 
2017 (Praena et al., 2017), and some months later the experiment was 
performed, with all the support of the n_TOF collaboration (The n_TOF 
collaboration). 
The n_TOF facility at CERN in Geneva makes use of the PS high- 
energy proton beam to produce a broad energy range neutron beam 
via spallation into a lead target. The generated neutrons are guided 
through beam pipes to two experimental areas (EAR-1 and EAR-2) 
located 185 and 20 m away from the target, respectively. At these lo-
cations, samples are placed at the neutron beam and the reaction 
products are detected. Provided the long path lengths, the energy of the 
neutrons can be obtained with high precision from the detection time of 
flight at the experimental areas. 
The measurement of the 14N (n,p)14C reaction was carried out during 
September–October 2017 at the EAR-2. Two detection systems were 
used; one of them based on MicroMegas detectors, which are charged 
particle gaseous detectors with a high neutron and gamma transparency. 
These features allow using them at in-beam conditions, which further 
improves the geometrical detection efficiency. The other detection sys-
tem was based on Double-Sided Silicon Strip Detectors (DSSSD), which 
can provide information on the angular distribution of the reaction 
products, and also profits from a reduced background due to their off- 
beam positioning. Fig. 1 shows both detection systems. 
The preliminary results from the measurement report a slightly lower 
value for the thermal cross-section compared to the reference evalua-
tions. The energy region accessed with the MicroMegas setup ranged 
from the thermal point to 60 keV. Along this region, the 1/v relation for 
the cross-section was verified, in good agreement with previous mea-
surements and evaluations. Fig. 2 shows the measurement compared 
with the ENDF evaluation and the previous data in the same energy 
range. 
Also, we have measured two neutron capture reactions on 35Cl: (n,p) 
(Praena et al., 2017) and (n,γ) (Porras et al., 2018a). This is an element 
especially present in brain and skin, and it can play a non-negligible role 
in neutron transport and delivered dose. We have estimated with Monte 
Carlo simulations the role of these reactions and we have found that the 
photons of up to 8.5 MeV emitted by the radiative capture of 35Cl, at the 
concentration typical in brain, may account at certain depths (between 3 
and 5 cm) of up to 12% of the total dose in normal brain, in the absence 
of boron, as illustrated in Fig. 3. The measurement of this reaction, 
performed in n_TOF at the experimental area EAR-1 with C6D6 liquid 
scintillators, is under analysis. 
2.2. Radiobiological data for BNCT treatment planning 
The different dose components of BNCT may have different biolog-
ical effectiveness due to differences in their linear energy transfer. 
Therefore, a “biological” or “weighted” dose (DW) is defined as the sum 
of the dose components weighted with different factors wi (Goorley 
et al., 2002; IAEA, 2001), previously called relative biological effec-
tiveness (RBE) factors (Coderre and Morris, 1999): 
DW ¼wf Df þ wtDt þ wγDγ þ wBDB (1) 
The quantity Dw is interpreted as the equivalent photon dose which 
produces the same effect than the BNCT procedure and is expressed in 
Gy-Eq or Gy(W). The weighting factors wi are defined as the ratio of the 
reference photon irradiation dose and the value of the physical dose 
component which is needed to produce the same effect. 
The weighting factors wi are a major source of uncertainty in the 
estimation of the treatment outcome of BNCT, for different reasons: (i) 
they are dose-dependent and cannot be strictly applied to other dose 
components than those for which were obtained, (ii) the current values 
used were obtained for brain tumor therapy, and because of a lack of 
knowledge for other tissues, they are also used for other type of tumors, 
(iii) the thermal and fast dose values, which were not possible to sepa-
rate in previous experiments, are assumed to take the same value, and 
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(iv) the gamma dose is assumed to be 1, although there is some evidence 
of the need of a dose reduction factor due to the smaller dose rate for this 
component in BNCT in comparison to conventional radiotherapy. 
Our group is performing research towards overcoming these draw-
backs. A resolution for most of them consists of adopting the formalism 
of the photon isoeffective dose developed by Gonz�alez and Santa Cruz 
(Gonzalez and Santa Cruz, 2012). In this formalism the photon iso-












DiDj ¼ αRDR þ Gðθ’ÞβRD2R ​ ; (2)  
where αi, βi are the coefficients of the Linear-Quadratic model for the 
dose component Di (i¼ f ; t; γ;BÞ and GðθÞ denoted the Lea-Catcheside 
time factor. However this formalism requires accurate values for all 
the coefficients. For example, the βi coefficients on which the synergies 
between different types of radiation strongly depend, are small and 
difficult to extract accurately from mixed-field measurements (quasi-
linear dependence errors). 
For obtaining the coefficients accurately, the optimal data should 
come from irradiations from different beams where the set of values 
(Dt ; Df ; Dγ ; DBÞ are linearly independent. We have designed an exper-
imental campaign for in-vitro samples at three facilities: a pure low 
energy neutron beam, as the cold neutron line PF1b of the Institute Laue- 
Langevin (ILL) of Grenoble (France) with different conditions for the 
cells, an epithermal neutron beam as the accelerator-based neutron 
source HispaNoS of the National Accelerator Center of Seville (CNA) and 
a hospital LINAC for conventional radiotherapy. The different type of 
irradiations and the dominating components of the dose delivered are 
displayed in Table 1. 
We have started the radiobiology measurements at ILL with a pure 
cold neutron beam and the first results have been published (Pedro-
sa-Rivera et al., 2020a). 
Additionally, we have proposed a simplified formalism for a first 
order approximation of the photon isoeffective dose, based on new 
weighting factors, defined as the ratio of the alpha coefficients of the 
different radiations: Wi ¼ αi=αp. This formalism (Pedrosa-Rivera et al., 
2020b) can be summarized in the Equations: 































where Dp is the approximation to a single-fraction photon isoeffective 
dose, and n stands for the number of sessions of dose dp of a fractionated 
photon isoeffective treatment. The new weighting factors, which are 
true constants, can be estimated from the previous ones or can be 
measured from radiobiology measurements. 
In addition to the suitability of the PF1b line at ILL for radiobiology 
measurements, this facility is very adequate for in-vitro tests of new 
boron compounds. We have started in vitro studies of boron rich com-
pounds, which will include uptake measurements for different cell lines, 
both tumor and normal, using both ICP-AES at UGR and boron autora-
diography under collaboration with the group of Pavia (Italy). The 
response of cells cultured with the boron compounds and the CBE 
measurement will be performed at the PF1b neutron line at ILL, for 
which a proposal has been approved (Porras et al., 2018b). A high 
neutron flux (thermal capture equivalent flux above 2 � 109 n/(s cm2)) 
guarantees accurate measurements in a short time (irradiations of a few 
minutes). A class 2 biological laboratory has been installed in the same 
Fig. 1. The two detection systems used for the measurement of the 14N (n,p)14C reaction at n_TOF. The picture on the left shows the MicroMegas setup and the 
picture on the right shows the DSSSD setup. 
Fig. 2. Preliminary estimations of the cross-section of the 14N (n,p)14C reac-
tion (green dots) in the thermal region, compared to the ENDF-8 evaluation in 
black and previous measurements data (Koehler et al., 1989) in red. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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instruments hall, which makes possible processing the cells just after the 
irradiation. We are open to establish collaborations for testing new 
boron compounds at this facility. 
3. Potential new strategies 
3.1. Sulfur-33 as a cooperative capturer for BNCT 
We have performed preliminary studies on potential use of 33S as an 
additional neutron capturer for enhancing BNCT, the reason being the 
important role played by sulfur in biochemistry and the enhanced high 
sulfur concentrations (of the order of mg/g) found in different tumors, 
addressed to an enhanced synthesis of glutathione (Gamcsik et al., 
2012). 33S is one of the few isotopes in the nuclear chart for which the 
dominant neutron capture reaction leads to alpha emission instead to 
photon emissions. However, its cross section was assumed to be more 
than three orders of magnitude smaller than that of boron, although 
there were no previous experimental data below 10 keV and important 
discrepancies were found between reported data above this quantity. 
For this reason our group performed recently measurements of this cross 
section at CERN and ILL. Two measurements were performed at n_TOF 
(CERN), at experimental areas EAR-1 and EAR-2, for measuring the 
epithermal and thermal region respectively, and another measurement 
at the thermal energy was performed at the PF1b line at ILL. 
The results, illustrated in Fig. 4, show that there is a 1/v dependence 
on the cross section at energies below 10 keV and a high resonance, with 
peak value above 25 b at 13.5 keV (Praena et al., 2018). However the 
thermal cross section value extracted from the experiments is still below 
1 b. Therefore, the potential use of 33S in BNCT depends on the possi-
bility of using neutron beams with a high component at such energy, 
which would lead to resonance captures from primary neutrons before 
thermalization and would enhance the dose at small depths (Porras 
et al., 2014). 
3.2. Neutron-guided BNCT 
Cold neutrons, those arising from a moderator at low temperatures, 
have a large wavelength and can be guided and focused through guides 
and lenses at large distances. At these guides, those low energy neutrons 
impinging on the walls at small angles travel by zig-zag or Garland re-
flections while those of higher energies cross the walls and are lost from 
the beam. This feature allows also focusing the beam enhancing the 
neutron flux in a small surface, of submilimeter size (the size of a 
catheter that can be inserted into the body). 
Such neutrons, when entering a boron-loaded tissue would produce a 
very high local dose, as the capture cross sections increases with 
decreasing energy (1/v) behaviour. Although it would be a very poorly 
penetrating beam, it would have the ability of be directed to a particular 
spot, which could be appropriate for some radiosurgery applications. We 
are conducting basic studies by means of simulations with the code 
McStas (Lefmann and Nielsen, 1999) (used for guiding cold neutrons) 
and MCNPX (Pelowitz, 2005) (for the transport in the tissue and the 
evaluation of the delivered dose) for studying this challenging potential 
application. 
In Fig. 5, it is illustrated the concentration produced for a cold 
neutron beam of 1 meV in a focusing guide of 2 m length, starting from a 
section of 10 � 10 cm to a 5 � 5 cm exit one (Porras et al., 2020). In the 
figure we have plotted that ratio between the dose that would be 
delivered to a phantom of a standard soft tissue in tumor (assumed 
loaded with a concentration of boron of 35 ppm) and the maximum 
value of the dose produced at normal tissue (for which a boron con-
centration of 10 ppm is assumed). Regions where this ratio is less than 
one are not coloured. 
4. NeMeSis: an accelerator-based facility for BNCT and other 
scientific applications 
The project NeMeSis (Neutrons for Medicine and Scientific applica-
tions) is based on an electrostatic accelerator able to produce a proton 
beam of 2.1 MeV at a current of 30 mA, which is already available in the 
market (Neutron Therapeutics and Inc). In our design, a solid lithium 
target on a copper backing refrigerated by microchannels designed in 
collaboration with the Laboratori Nazionale di Legnaro (Italy) (Mastinu 
et al., 2015) will be used for the neutron production. Preliminary esti-
mations with the ANSYS code and tests under the proton accelerator of 
Birmingham show that this system is able to dissipate power up to 3 
kW/cm2. The idea is to make use of a low cost target that can be replaced 
frequently, which would avoid blistering problems. Our estimations of a 
beam shape assembly which is currently under optimization would 
produce a pure epithermal neutron beam, as the low proton energy 
would produce neutrons up to a maximum energy of 0.35 MeV, which 
require less moderation than most options conceived for BNCT. 
Fig. 3. Dose components due to the most relevant individual reactions, in brain tissue, as a function of depth, estimated with Monte Carlo simulations.  
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This neutron beam will be used for performing clinical trials for the 
treatment of brain tumors (including GBM) and recurrent head and neck 
cancers. In addition to this, we plan to perform the previous studies 
required for other applications such as the treatment of liver metastases 
of colorectal cancers without autotransplantation (due to the expected 
penetrability of the beam), soft tissue sarcomas, some type of lung tu-
mors, local recurrences of breast or pancreatic cancers. 
In this facility the production of medical radioisotopes for diagnosis 
will be also pursued. In particular our group has recently studied the 
production of very short lived PET radioisotopes (11C, 13N and 15O) with 
a deuteron beam (Arias de Saavedra et al., 2018) that could be extracted 
from a second line from the same accelerator used for the neutron beam 
production for BNCT. In addition to this, the production of radioisotopes 
by neutron capture as 99Mo (parent of 99mTc, for which there are several 
supply concerns (European Nuclear Society)) can be explored from the 
epithermal flux from the lithium target. This is feasible when the 
neutron capture resonance integral in the epithermal range is specially 
large, as in the case of 98Mo (50 times larger than the thermal value). All 
these are very interesting possibilities to explore because any of them 
may make a BNCT facility more sustainable and therefore more attrac-
tive for investments. 
The scheme of the NeMeSis facility is sketched in Fig. 6. 
We intend to perform the preliminary studies for using the facility 
towards other scientific applications. Neutrons are very important as a 
tool for very different fields of science and technology, ranging from the 
study of radiation damage in circuits, radiation protection for space 
missions or neutron scattering, which has a great amount of applications 
in material sciences and structural biology. This latter possibility would 
require the use of a neutron cooler (e.g. moderator of liquid deuterium at 
25 K) in order to produce a cold neutron beam similar to those of existing 
facilities. 
Granada is the official European candidate for the facility IFMIF- 
DONES (Irradiation of Fusion Materials International Facility – Demo 
Oriented Neutron Source), which is aimed to produce a huge neutron 
Table 1 
In-vitro experiments planned and relative role of the dose components.  
Setup Dt  Df  Dγ  DB  
Pure cold neutron 





Dominant 0 Small 0 
Pure cold neutron 









Pure cold neutron 









Pure cold neutron 




medium, with boron 







Epithermal beamb and 
minimal culture 
medium 
Small Dominant Small 0 
Epithermal beamb and 
minimal culture 
medium, with boron 




Epithermal beamb and 
large culture 
medium 
Relevant Relevant Relevant 0 
Epithermal beamb and 
large culture 
medium, with boron 




Hospital linacc at dose 
rate similar to the 
BNCT gamma 
component 
0 0 Dominant 0  
a Cold neutron beam correspond to that of the PF1b line at ILL. 
b Epithermal beam refers to the one produced by the 7Li (p,n) reaction near 
the threshold at CNA, Seville and. 
c Hospital Linac is the Elekta Versa HD™ accelerator at the Granada Univer-
sity hospital “Virgen de las Nieves”. 
Fig. 4. Cross section values for the 33S (n,α) reaction measured at n_TOF and 
normalized to the thermal value from the ILL measurement. High resonances in 
the epithermal region have been confirmed. 
Fig. 5. Ratio of dose at tumor with respect to the maximum dose at normal 
tissue produced by an original cold beam of 10 � 10 cm (above) and the result 
of focalizing the beam at 5 � 5 cm (below). 
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flux in order to test materials for the future DEMO fusion reactor. It is 
planned to accelerate deuterons up to 40 MeV with a current of 125 mA 
and using a liquid lithium target in order to produce an unprecedented 
neutron flux (Ibarra et al., 2019). This is a long term project that could 
benefit from the previous construction and use of the NeMeSis facility, 
since this would allow conducting preliminary studies of neutron ap-
plications that could be performed in a future to the neutron source 
DONES. 
5. Conclusions 
The activities on BNCT research of the Granada group have been 
described. They are possible thanks to collaboration with different 
groups. In particular we want to stress the potential use of two inter-
national facilities for basic research: (i) the neutron time of flight at 
CERN, of which we are part of the collaboration, and which is optimal 
for neutron cross section measurements, and (ii) the Institute Laue- 
Langevin where a biology laboratory has been installed close to a very 
clean low energy neutron beam, perfectly suitable for radiobiology 
studies and in-vitro test of boron compounds, for which we have pro-
posals already accepted. We are open to collaborations with other 
groups with the same research interest. 
With respect to clinical BNCT research, it is our aim is to build a 
facility that would allow performing clinical trials in a future. We are 
optimizing an accelerator-based design that will expand the type of 
cancers treated with BNCT. In addition to this, this facility intends to be 
a prototype of theranostic facility where the production of radioisotopes 
will allow developing new nuclear medicine procedures. 
Our group is honored to host the next International Congress on 
Neutron Capture Therapy, which will be the 19th edition and will take 
place in Granada, Spain in June 2021 (www.icnct19. org). 
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